Unlabelled: proBNP represents the precursor of the brain natriuretic peptide (BNP) and is released by the cardio-myocytes as a result of the myocardial stretch. It is fractioned into two components, BNP and NT-proBNP. We use more often the determination of NT-proBNP levels in laboratory tests because of its prolonged biological half-time (60-120 minutes, much longer than the BNP half-life).

Aim: To determine a link between the plasmatic levels of NT-proBNP and heart failure syndrome (HFS).

Material And Method: We studied 40 patients admitted in the Internal Medicine Clinic of the Western University "Vasile Goldiş" Arad, during a two years period (2004-2005). Every patient had a clinical examination, an echocardiography and the determination of NT-proBNP levels. For the determination of the BNP plasmatic levels we used a special kit Elecsys proBNP, which is now largely available. The NT-proBNP levels were correlated with the HFS diagnosis (the presence of dyspnea and the ejection fraction).

Results: In 29 patients the NT-proBNP levels were above the upper limit of 125 pg/ml, 86% of them being clinically diagnosed with HFS. 11 patients had BNP levels in the normal values range and 4 of them were clinically diagnosed with HFS. Correlating the NT-proBNP plasma levels and NYHA class of HF we could establish some guidelines regarding the critical BNP values upon which the diagnostic of HFS is almost certain. The minimum level of BNP at which a patient was diagnosed with HF was 89.9 pg/ml. Levels above 125 pg/ml predicts o risk six times higher for HFS.

Discussions: The BNP plasma values may be modified in hepatic or renal failure, which can cause false high levels of hormone. These situation should be considered possible error sources of diagnosis if the HFS is evaluated only by the means of NT-proBNP plasma levels.

Conclusions: The dosage of plasma levels of NT-proBNP is useful into patients with suspected HFS, if the other methods of diagnosis are not reliable. There is a link between the NT-proBNP plasma levels and the NYHA HFS class. However only the dosage of BNP is not sufficient for a correct diagnosis of HFS.

Download full-text PDF

Source

Publication Analysis

Top Keywords

nt-probnp plasma
16
plasma levels
16
nt-probnp levels
16
levels
13
nt-probnp
11
bnp
9
heart failure
8
determination nt-probnp
8
plasmatic levels
8
levels nt-probnp
8

Similar Publications

Background: Plasma metabolites could be suitable as predictive biomarkers for cardiovascular pathologies or death, thereby improving the prediction of protein biomarkers. The release of acylcarnitines may be altered after coronary artery disease (CAD) in subjects with recurrent clinical outcomes, and this could be used as a prognosis tool.

Methods: Patients with stable coronary artery disease (SCAD) who had suffered an acute coronary syndrome 6-9 months before were followed for up to 4.

View Article and Find Full Text PDF

Introduction And Aim: Assessing decongestion in patients with acute decompensated heart failure (ADHF) is challenging, requiring multiple parameters and often remaining imprecise. The study aimed to investigate the utility of indirectly estimating plasma variation (∆ePVS) for evaluating decongestion in ADHF patients in relation to natriuretic peptides.

Materials And Methods: This prospective, observational, single-center study included 111 patients (mean age 74 years, 40% female) hospitalized with ADHF and treated with intravenous diuretics along with optimized medical therapy.

View Article and Find Full Text PDF

Background: Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards.

Methods: Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.

View Article and Find Full Text PDF

Background And Aims: Meteorin-like protein (Metrnl) has been recently suggested as a new adipokine with protective cardiovascular effects. Its circulating levels in patients seem to be associated with heart failure (HF), although with contradictory results. Our aim was to ascertain whether this adipokine could estimate the prognosis of HF in de novo HF (DNHF) patients.

View Article and Find Full Text PDF

Background: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and causes major adverse cardiovascular events (MACE). SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing 1) is a large extracellular matrix protein that is detectable in the plasma. However, it is unknown whether adding plasma SVEP1 levels to clinical predictors including NT-proBNP (N-terminal pro-B-type natriuretic peptide) improves the prognostication in patients with hypertrophic cardiomyopathy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!